Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
May 13, 2024 08:50 ET
|
Outlook Therapeutics, Inc.
UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the...
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
May 09, 2024 08:45 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® to Present at the Retina World Congress 2024
May 02, 2024 09:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
April 29, 2024 09:00 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
April 15, 2024 16:15 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
March 22, 2024 07:35 ET
|
Outlook Therapeutics, Inc.
Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days ISELIN, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Outlook...
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
March 18, 2024 17:10 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of...
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
March 12, 2024 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic...
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
February 14, 2024 08:05 ET
|
Outlook Therapeutics, Inc.
NORSE EIGHT underway with first subject dosed and additional clinical sites beginning enrollment Continue to expect planned resubmission of the ONS-5010 Biologics License Application (BLA) by the end...
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
January 31, 2024 08:05 ET
|
Outlook Therapeutics, Inc.
NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Biologics License Application (BLA) by the end of...